摘要
目的 探讨达格列净联合诺欣妥对非糖尿病急性心肌梗死患者急诊介入治疗术后心力衰竭(心衰)的疗效观察。方法 选取2021年6月至2022年6月就诊于新乡医学院第三附属医院的非糖尿病急性心肌梗死行急诊经皮冠状动脉介入治疗(PCI)术后患者100例为研究对象,按照随机数字表法分为对照组(应用诺欣妥)和观察组(在对照组基础上联用达格列净)各50例。治疗1周后,观察两组24 h尿量、尿酸(UA)、超敏C反应蛋白(hs-CRP)、N末端脑钠肽前体(NT-pro BNP);治疗3个月,记录两组左室收缩末期内径(LVESD)、左室舒张末期内径(LVEDD)、左室射血分数(LVEF)、6min步行距离(6MWD)及随访期间主要心血管不良事件(MACE)和不良反应情况。结果 治疗1周后,两组NT-proBNP、hs-CRP、UA均低于治疗前(P<0.05),且观察组降低明显(P<0.05),24 h尿量水平均高于治疗前(P<0.05),且观察组升高明显对照组(P<0.05);治疗3个月后,两组LVESD、LVEDD均较治疗前降低(P<0.05),且观察组下降明显(P<0.05),LVEF、6MWD水平均较治疗前升高(P<0.05),且观察组升高更为明显(P<0.05),观察组发生MACE发生率较低,差异有统计学意义(P<0.05);两组不良反应率比较,差异无统计学意义(P>0.05)。结论 达格列净联合诺欣妥治疗非糖尿病急性心肌梗死患者行急诊PCI术后心力衰竭的疗效优于单用诺欣妥治疗,可改善心功能和心室重构,降低MACE发生率,且安全性良好。
Objective To investigate the effect of Dapagliflozin combined with Entresto in treating heart failure after emergency interventional therapy in non-diabetic acute myocardial infarction patients.Methods A total of 100 cases of non-diabetic acute myocardial infarction patients treated in the Third Affiliated Hospital of Xinxiang Medical College from June 2021 to June 2022 after emergency interventional treatment of heart failure were selected as the study objects.Moreover,the patients were randomly divided into a control group(Entresto) and an observation group(control group combined with Dapagliflozin) with 50 cases each.After one week of treatment,24 h urine volume,uric acid(UA),hypersensitive C-reactive protein(hs-CRP),and N-terminal B-type natriuretic peptide(NT-proBNP) were observed in both groups before and after treatment.After three months of treatment,left ventricular end-systolic diameter(LVESD),left ventricular end-diastolic diameter(LVEDD),left ventricular ejection fraction(LVEF),6-min walking distance(6MWD),and major cardiovascular adverse events(MACE) and adverse reactions during follow-up were recorded.Results After one week of treatment,NT-proBNP,hs-CRP,and UA in both groups were lower than before treatment(P<0.05) and decreased in the observation group(P<0.05),24-hour urine volume levels were higher than before treatment(P<0.05),and increased in the observation group(P<0.05);After three months of treatment,LVESD and LVEDD were decreased in both groups compared with before treatment(P<0.05) and decreased in the observation group(P<0.05),LVEF and 6MWD levels were increased compared with before treatment(P<0.05),and increased in the observation group(P<0.05),and the incidence of MACE was lower in the observation group.The difference was statistically significant(P<0.05).There was no significant difference in the adverse reaction rate between the two groups(P>0.05).Conclusion The efficacy of Dapagliflozin combined with Entresto in the treatment of heart failure after emergency interventional therapy in
作者
苏鹏
杨秀丽
Su Peng;Yang Xiuli(The First Department of Cardiology,the Third Affiliated Hospital of Xinxiang Medical College,Xinxiang 453000,Henan,China;不详)
出处
《中国循证心血管医学杂志》
2023年第8期970-973,共4页
Chinese Journal of Evidence-Based Cardiovascular Medicine
关键词
心肌梗死
心力衰竭
达格列净
诺欣妥
Myocardial infarction
Heart failure
Dapagliflozin
Entresto
